CorMedix Inc. - Common Stock (CRMD)

CorMedix posts strong Q3 results with $104 million in revenue, higher DefenCath sales, and raises 2025 guidance following Melinta integration progress.

The company now expects pro forma net revenue for the full year in a range of $390 million to $410 million, higher than a Wall Street estimate of $283.66 million.

CorMedix Inc. (CRMD) Q3 2025 earnings show a revenue beat of $104.3M, but an EPS miss. The stock rose in pre-market trading on strong sales growth.

CorMedix (CRMD) excels in a proven growth stock strategy, showing massive sales growth, strong earnings momentum, and solid profitability metrics.

Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle.

CorMedix Inc. fits a proven growth investing strategy with explosive revenue growth, soaring profits, and strong analyst revisions, signaling high potential.

CorMedix Inc (CRMD) identified as a top growth stock using Louis Navellier's strategy, showing explosive revenue growth, soaring earnings estimates, and strong profitability.

CorMedix (CRMD) excels in Louis Navellier's growth strategy with massive revenue growth, soaring earnings, and high ROE, making it a top stock to watch.

Discover how CORMEDIX INC (CRMD) aligns with Louis Navellier’s growth investing strategy, showcasing strong earnings momentum, rapid revenue growth, and high ROE for potential stock gains.

Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.

Performance Food rejects offer; Lufthansa drops Air Europa bid; NFL inks deal with ESPN; Claire's files bankruptcy amid retail struggles.

CorMedix Inc (CRMD) reported strong Q2 2025 earnings, beating revenue and EPS estimates, with shares rising in pre-market trading. The company also announced the acquisition of Melinta Therapeutics.

CorMedix boosts Q2 sales forecast as a major dialysis client accelerates DefenCath use, prompting positive analyst coverage and growth outlook.

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

The offering follows an upward revision to CorMedix’s Q2 revenue forecast, driven by faster-than-expected rollout of its FDA-approved DefenCath therapy across an extensive dialysis network.